BioSyent Inc. (RX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello. Welcome to the Q4 and full fiscal year 2025 results presentation for Bioscient Inc. My name is Rene Gorham and I'm the president and CEO of the company. Today you'll hear that we closed out a very solid year in 2025 and today's presentation will touch on our recent oral science acquisition. but the results that I'll be reviewing with you are for the period ended December 31st, 2025, which is before our March acquisition date of Oral Science. I will be discussing Oral Science, but for more detail on the transaction, I encourage you to also look at our February 9th deal announcement press release and our March 2nd deal closing press release and our MD&A and financial statements for the period that I'm reporting on for you today. I want to draw your attention to our forward-looking disclaimer. No doubt I will be making some forward-looking statements in today's presentation. Since I presented to you last, there have been some changes in our brand slide. So you see now we've added a number of the brands that are promoted and distributed by Oral Science and added those to our specialty pharmaceutical brands as well. So back to a Bioscience Inc. ending December 31st presentation. This is X, any business results from Oral Science. So you see for the quarter, our revenue reached just under $9.7 million. up 10% from the year ago. That's Canadian Pharma, International Pharma and our legacy business. Our EBITDA for the period was just over 2.5 million. That's up 13% to the year ago. And our net income after tax was just under $2 million, a lift of 23% versus the year ago. And you see that both our EBITDA and our NEAT margins stayed strong for the quarter. On a full year basis, our revenue exceeded $43 million, and that was up 23% to the year ago. Once again, Canadian pha...